Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma

BACKGROUND: While gemcitabine/cisplatin (GC) is the gold standard regimen for patients with advanced urothelial carcinoma (aUC), either dose-reduced GC or gemcitabine/carboplatin (GCa) is an alternative option for “cisplatin-unfit” patients. However, few studies have compared outcomes with these com...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugimoto, Kazuma, Taguchi, Satoru, Kishitani, Kenjiro, Kawai, Taketo, Masuda, Kazuki, Nakamura, Yu, Kinjo, Manami, Tambo, Mitsuhiro, Miyakawa, Jimpei, Akiyama, Yoshiyuki, Yamada, Yuta, Sato, Yusuke, Yamada, Daisuke, Nakagawa, Tohru, Fukuhara, Hiroshi, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647899/
https://www.ncbi.nlm.nih.gov/pubmed/36352389
http://dx.doi.org/10.1186/s12894-022-01139-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647899/
https://www.ncbi.nlm.nih.gov/pubmed/36352389
http://dx.doi.org/10.1186/s12894-022-01139-9

Ejemplares similares